Authors:
O'Donnell, MR
Appelbaum, FR
Baer, MR
Carabasi, MH
Coutre, SE
Erba, HP
Estey, E
Glenn, MJ
Kraut, EH
Maslak, P
Millenson, M
Miller, CB
Saba, HI
Stone, R
Tallman, MS
Citation: Mr. O'Donnell et al., NCCN Practice Guidelines for acute myelogenous leukemia, ONCOLOGY-NY, 14(11A), 2000, pp. 53-61
Authors:
Chauncey, TR
Rankin, C
Anderson, JE
Chen, IM
Kopecky, KJ
Godwin, JE
Kalaycio, ME
Moore, DF
Shurafa, MS
Petersdorf, SH
Kraut, EH
Leith, CP
Head, DR
Luthardt, FW
Willman, CL
Appelbaum, FR
Citation: Tr. Chauncey et al., A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and theMDR modulator PSC 833: a Southwest Oncology Group study 9617, LEUK RES, 24(7), 2000, pp. 567-574
Authors:
Karanes, C
Kopecky, KJ
Head, DR
Grever, MR
Hynes, HE
Kraut, EH
Vial, RH
Lichtin, A
Nand, S
Samlowski, WE
Appelbaum, FR
Citation: C. Karanes et al., A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia, LEUK RES, 23(9), 1999, pp. 787-794